Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.48 |
| ▸ | CTSL | P07711 | 7/20 | 0.48 |
| ▸ | CTSS | P25774 | 7/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5092925 | 0.86 | KMT2A (0.45) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4687332 | 0.83 | CTSK (0.51) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6403087 | 0.82 | PTPN1 (0.41) | CTSKCTSLCTSSCTSBMCHR1 | |
| SCHEMBL5096736 | 0.80 | KMT2A (0.45) | CTSKCTSLCTSS | |
| SCHEMBL6405643 | 0.80 | CTSK (0.48) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5096711 | 0.78 | ALDH1A1 (0.43) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5099108 | 0.78 | CTSK (0.51) | CTSKCTSLCTSSCTSB | |
| SCHEMBL5105422 | 0.77 | CTSK (0.41) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5099236 | 0.77 | CTSK (0.67) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5099669 | 0.76 | LMNA (0.40) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885CTSL 25/4885CTSS 10/4885 |
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | CTSK 47/4885CTSL 20/4885CTSS 15/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | CTSK 1/4885CTSL 19/4885CTSS 4/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885CTSL 25/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.